文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

低中危前列腺癌根治性放疗后早期PSA动力学特征

Early Prostate-Specific Antigen Kinetics for Low- and Intermediate-Risk Prostate Cancer Treated With Definitive Radiation Therapy.
PubMed 文献 · Pract Radiat Oncol · 2021-07-21

本研究用患者特异性模型分析1042例低中危前列腺癌患者接受常规分割、大分割、立体定向体部放疗或近距离放疗后24个月内PSA动力学,发现消融性治疗PSA谷值更高且出现延迟反应,PSA下降速率在6-24个月更快,PSA反弹发生率13.3%且不受治疗方式影响。

要点

  • 消融性治疗(SBRT、高剂量率)的PSA谷值绝对值及相对初始PSA均更高。
  • 非消融治疗超50%达到PSA谷值≤0.5 ng/mL,SBRT仅23%、高剂量率33%。
  • 年轻、初始PSA高于中位数、PSA反弹及消融治疗是不达PSA谷值≤0.5 ng/mL的预测因素。

核心结论

  • 放疗后24个月内,消融性治疗与延迟PSA反应和更高PSA谷值相关,PSA下降速率在潜伏期后更快。

研究设计与样本

  • 回顾性分析1998-2018年单家NCI指定综合癌症中心1042例低中危前列腺癌患者, demographics和治疗特征前瞻性收集。

主要发现

  • 1042例中45%低危、37%有利中危、19%不利中危;PSA谷值中位时间14.8-17.1个月。
  • 非消融治疗超50%达到PSA谷值≤0.5 ng/mL,SBRT为23%,高剂量率近距离放疗为33%。
  • PSA反弹发生率13.3%,不受治疗方式、Gleason评分或前列腺体积影响。
  • 6-24个月期间消融性治疗PSA下降速率更快。
  • 多因素logistic建模显示年轻、初始PSA高于中位数、存在PSA反弹及消融治疗是未达PSA谷值≤0.5 ng/mL的预测因素。

关键数值与推荐

  • PSA谷值≤0.5 ng/mL阈值:非消融治疗超50%达到,SBRT 23%,高剂量率33%。
  • PSA反弹发生率13.3%。
  • PSA谷值中位时间14.8-17.1个月。

临床怎么用

  • 解读低中危前列腺癌放疗后24个月内PSA时需考虑治疗方式特异的动力学特征,消融性治疗PSA谷值更高且下降延迟。
  • PSA反弹常见且不影响治疗方式判断,需结合动力学特征评估治疗反应和监测复发。

局限性

  • 回顾性分析来自单中心,可能限制普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study used a patient-specific model to characterize and compare ideal prostate-specific antigen (PSA) kinetics for low- and intermediate-risk prostate cancer after definitive radiation treatment with conventionally fractionated, hypofractionated, stereotactic body radiation therapy, or brachytherapy, both high-dose and low-dose rate. METHODS AND MATERIALS: This retrospective analysis includes low- and intermediate-risk patients with prostate cancer treated between 1998 and 2018 at an National Cancer Institute-designated comprehensive cancer center. Demographics and treatment characteristics were prospectively collected. Patients had at least 2 PSA measurements within 24 months of treatment and were free from biochemical recurrence. The incidence of, time to, and risk factors for PSA nadir (nPSA) and bounce (bPSA) were analyzed at 24 months after radiation therapy. Ideal PSA kinetics were characterized for each modality and compared. RESULTS: Of 1042 patients, 45% had low-risk cancer, 37% favorable intermediate risk, and 19% unfavorable intermediate risk. nPSAs were higher for ablative modalities, both as absolute nPSA and relative to initial PSA. Median time to nPSA ranged from 14.8 to 17.1 months. Over 50% treated with nonablative therapy (conventionally fractionated, hypofractionated, and low-dose rate) reached an nPSA threshold of ≤0.5 ng/mL compared with 23% of stereotactic body radiation therapy and 33% of high-dose rate cohorts. The incidence of bPSA was 13.3% and not affected by treatment modality, Gleason score, or prostate volume. PSA decay rate was faster for ablative therapies in the 6- to 24-month period. CONCLUSIONS: Analysis of PSA within 24 months after radiation therapy revealed ablative therapies are associated with a latent PSA response and higher nPSA. Multivariable logistics modeling revealed younger age, initial PSA above the median, presence of bPSA, and ablative therapy as predictors for not achieving nPSA ≤0.5 ng/mL. PSA decay rate appears to be faster in ablative therapies after a latent period. Understanding the different PSA kinetic profiles is necessary to assess treatment response and survey for disease recurrence.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pirlamarla AK, Hansen CC, Deng M, et al. Early Prostate-Specific Antigen Kinetics for Low- and Intermediate-Risk Prostate Cancer Treated With Definitive Radiation Therapy. Pract Radiat Oncol. 2021. PMID: 34303033. doi:10.1016/j.prro.2021.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。